PT - JOURNAL ARTICLE AU - Golan, Yarden AU - Prahl, Mary AU - Cassidy, Arianna G. AU - Gay, Caryl AU - Wu, Alan H.B. AU - Jigmeddagva, Unurzul AU - Lin, Christine Y. AU - Gonzalez, Veronica J. AU - Basilio, Emilia AU - Warrier, Lakshmi AU - Buarpung, Sirirak AU - Li, Lin AU - Asiodu, Ifeyinwa V. AU - Ahituv, Nadav AU - Flaherman, Valerie J. AU - Gaw, Stephanie L. TI - COVID-19 mRNA Vaccination in Lactation: Assessment of adverse effects and transfer of anti-SARS-CoV2 antibodies from mother to child AID - 10.1101/2021.03.09.21253241 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.09.21253241 4099 - http://medrxiv.org/content/early/2021/08/03/2021.03.09.21253241.short 4100 - http://medrxiv.org/content/early/2021/08/03/2021.03.09.21253241.full AB - Background Data regarding the rate of adverse effects observed in the lactating mother-infant dyad and their immune response to COVID-19 mRNA vaccination during lactation are needed to inform vaccination guidelines.Methods From a prospective cohort of 50 lactating individuals who received mRNA-based vaccines for COVID-19 (mRNA-1273 and BNT162b2), blood and milk samples were collected prior to first vaccination dose, immediately prior to 2nd dose, and 4-10 weeks after 2nd dose. Symptoms in mother and infant were assessed by detailed questionnaires. Anti-SARS-CoV-2 antibody levels in blood and milk were measured by Pylon 3D automated immunoassay and ELISA, and PEGylated proteins in milk were measured by ELISA. Blood samples were collected from a subset of infants whose mothers received the vaccine during lactation or pregnancy (4-15 weeks after mothers’ 2nd dose).Results No severe maternal or infant adverse effects were reported in this cohort. Two mothers and two infants were diagnosed with COVID-19 during the study period. Vaccine-related products, PEGylated proteins, were not found at significant levels in milk after vaccination. After vaccination, levels of anti-SARS-CoV-2 IgG and IgM significantly increased in maternal plasma and there was significant transfer of anti-SARS-CoV-2-Receptor Binding Domain (anti-RBD) IgA and IgG antibodies to milk. Milk IgA levels after 2nd dose were negatively associated with infant age. Anti-SARS-CoV-2 IgG antibodies were not detected in the plasma of infants whose mothers were vaccinated during lactation.Conclusions COVID-19 mRNA vaccines generate robust immune responses in plasma and milk of lactating individuals without severe adverse effects reported.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThese studies were supported by the Marino Family Foundation (to M.P), the National Institutes of Health (NIAID K23AI127886 to M.P. and NIAID K08AI141728 to S.L.G.), the Krzyzewski Family (to S.L.G), the Weizmann Institute of Science -National Postdoctoral Award Program for Advancing Women in Science (to Y.G.), the International Society for Research In Human Milk and Lactation (ISRHML) Trainee Bridge Fund (to Y.G.), and of the Human Frontier Science Program (to Y.G.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of California San Francisco (UCSF) institutional review board approved the study (20-32077, 20-30410).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be available